Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on German Health Review.
Press releases published on May 6, 2025
Balachandar Jeganathan Achieved Award-Winning Success in Season 1 of the 2025 TITAN Business Awards
EIN Presswire
·
May 6, 2025
The first season of the 2025 TITAN Business Awards has officially concluded, recognizing global business excellence across a wide range of industries. NEW YORK, NY, UNITED STATES, May 6, 2025 /EINPresswire.com/ -- The first season of the 2025 TITAN …
PIRCHE Partners with Virginia Commonwealth University to Expand User Base, Enhance Transplant Outcomes
EIN Presswire
·
May 6, 2025
VCU integrates PIRCHE’s technology to support donor selection and personalized immunosuppression. GRüNWALD, BAVARIA, GERMANY, May 6, 2025 /EINPresswire.com/ -- PIRCHE AG is pleased to announce that Virginia Commonwealth University has executed a …
IDCRAFT GmbH officially launched: A new specialist for RFID and Auto-ID hardware solutions
EIN Presswire
·
May 6, 2025
Our portfolio includes RFID reader modules, stationary readers, transponders and labels – perfectly suited for Auto-ID applications. NEUHOFEN, RHINELAND-PALATINATE, GERMANY, May 6, 2025 /EINPresswire.com/ -- ]With the founding of IDCRAFT GmbH, a new …
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
GlobeNewswire
·
May 6, 2025
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1 …
Topas Therapeutics’ TPM502 Achieves Gluten-specific Tolerance Induction, Positive Safety Profile in Phase 2a Trial in Celiac Disease Patients
GlobeNewswire
·
May 6, 2025
TPM502 achieved significant and dose-dependent reduction in IL-2 and IFN-γ release by gluten-specific T cells and durable immunomodulation of gluten-specific CD4+ T cells Patient-reported outcomes indicated dose-dependent reduction of symptoms following a …